HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Thursday, 22 March 2018

February’s CEAs.....

Our quick search for CEA’s published in February uncovered 51 articles.   In the right-hand column of this blog is a CEA Archive, which includes our CEA search results by month.  Below are those in our areas of interest.
  • Alemao E, Johal S, Al MJ, Rutten-van Molken M. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21(2):193-202.
  • Hernandez L, Lanitis T, Cele C, Toro-Diaz H, Gibson A, Kuznik A. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-effectiveness Analysis. Journal of managed care & specialty pharmacy. 2018:1-9.
  • Kumar V, Cohen JT, van Klaveren D, Soeteman DI, Wong JB, Neumann PJ, et al. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis. Annals of internal medicine. 2018;168(3):161-9.
  • Laiteerapong N, Cooper JM, Skandari MR, Clarke PM, Winn AN, Naylor RN, et al. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Annals of internal medicine. 2018;168(3):170-8.
  • Russell LB, Bhanot G, Kim SY, Sinha A. Using Cluster Analysis to Group Countries for Cost-effectiveness Analysis: An Application to Sub-Saharan Africa. Medical decision making : an international journal of the Society for Medical Decision Making. 2018;38(2):139-49.